NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIZZ (aceclidine) is an ophthalmic solution approved by the FDA on July 31, 2025, for use as eye drops. The mechanism of action and specific indications are not yet publicly detailed, but aceclidine is a cholinergic agent historically used in ophthalmology. This newly launched product represents LENZ Therapeutics' entry into the ophthalmic care market.
Growth17.7 years to LOE
Early-stage launch with 10 linked job openings indicates LENZ is actively building commercial infrastructure; significant hiring opportunity for field and support roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Started Aug 2022
59 enrolled
PresbyopiaRefractive ErrorsEye Diseases
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Started May 2022
68 enrolled
PresbyopiaRefractive ErrorsEye Diseases
Career Relevance
VIZZ launch presents 10 open positions across commercial, supply chain, and IT functions, with heavy emphasis on field sales and MSL roles. This is an early-stage launch window offering entry-level and mid-career professionals the opportunity to build a brand from its market introduction.
Worked on VIZZ at LENZ Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.